Anthropic and OpenEvidence Expand Medical AI Access
Anthropic and medical knowledge platform OpenEvidence are partnering to expand access to AI-powered clinical decision support. The initiative targets physicians in low- and middle-income countries with limited access to medical resources.
The companies announced the collaboration on September 22, 2026. Under the initiative, OpenEvidence will offer a specialised version of its platform free of charge to healthcare providers in about 100 countries.
The rollout includes countries such as Uganda, Angola, Sudan, Haiti, and Mongolia. Meanwhile, Anthropic will provide the underlying technology, while OpenEvidence will adapt the system to local healthcare conditions.
OpenEvidence Expands Clinical AI Access
OpenEvidence answers doctors’ questions using peer-reviewed medical research and treatment guidelines. The platform is already available at no cost to clinicians in the United States and Europe.
Now, the company wants to extend that access to regions where medical literature, specialist expertise, and continuing education can be harder to obtain. Therefore, the initiative focuses on providing access to clinical information rather than replacing physicians.
In August alone, US clinicians consulted OpenEvidence 42 million times, according to founder Daniel Nadler. Furthermore, Nadler said several hundred million Americans will have received care in 2026 from doctors who used the platform.
The international version will also account for differences between healthcare systems. Disease patterns, diagnostic resources, treatment availability, and infrastructure can vary significantly across countries. Consequently, OpenEvidence plans to adjust the platform for regional conditions.
OpenEvidence has already worked with health organisations in Rwanda and Botswana on this approach. In Rwanda, local doctors and nurses tested the system and provided feedback on its suitability for local care settings.
Anthropic Provides Technology Backend
Anthropic will supply the technology supporting the medical AI platform. Meanwhile, OpenEvidence will manage regional adaptation and account for local healthcare infrastructure.
The approach also reflects the practical limits of healthcare infrastructure in some target markets. For example, some medical facilities may face unreliable electricity supplies. However, physicians often have smartphones that can provide access to medical information.
OpenEvidence founder Daniel Nadler said the system is being designed to reflect local conditions. He described the initiative as “context adaptive” across the regions where it will operate.
Anthropic President Daniela Amodei said technology has advanced enough to support the expansion. However, she also said market incentives alone would not have supported the initiative without philanthropic involvement.
The companies have not disclosed financial terms for the collaboration. Therefore, the announcement currently provides details on access, technical support, and geographic expansion rather than on commercial arrangements.
Medical AI Raises Localisation Questions
The expansion comes as healthcare organisations increasingly examine generative AI for clinical support. Supporters say these systems can help physicians navigate large volumes of medical information more quickly.
However, medical AI also faces questions around accuracy and regional relevance. Systems trained mainly on data from wealthier countries may not fully reflect local clinical practices or available treatments.
Independent research also highlights the need for careful evaluation. A September 2026 study in Nature Medicine found that several general-purpose frontier models outperformed OpenEvidence and another specialised clinical AI tool across its selected benchmarks. The researchers called for independent, real-world evaluation before wider clinical deployment.
That context makes localisation a central part of the new initiative. OpenEvidence’s work with healthcare organisations in Rwanda and Botswana provides an early example of how the company is testing regional adaptation.
For now, the partnership will make specialised medical AI available to physicians across about 100 countries. The companies’ stated objective is to widen access to evidence-based clinical information while adapting the technology to local healthcare environments.
